Non-St-Elevation Myocardial Infarction

Risk for subsequent HF or death in the 5 years after STEMI or non-STEMI remains higher in women, compared with men, researchers reported in Circulation.

In patients who underwent PCI, trimetazidine, a drug to improve myocardial metabolism, did not improve angina recurrence or other CV outcomes, according to results of the ATPCI trial presented at the European Society of Cardiology Congress.